A Phase 2 interventional study of JTE-051 and Placebo in Rheumatoid Arthritis, sponsored by Akros Pharma Inc.. Completed at 39 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Arthritis, Rheumatoid with a site in Ukraine — 4 open to participants now, 8 under way, 1 of them phase 3. Arthritis, Rheumatoid · Ukraine.
Among the 118 studies in Arthritis, Rheumatoid with a site in Ukraine, this one is the 80th largest by enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2016, is one of 56 in phase 2, and was the 94th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 118 studies in Arthritis, Rheumatoid with a site in Ukraine are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Ukraine, United States, Belgium and 8 more countries
Ages 18–65
AstraZeneca · Sites in Ukraine, United States, Argentina and 14 more countries
Ages 18+
AstraZeneca · Sites in Ukraine, United States, Australia and 7 more countries
Ages 18–65
Lifordi Immunotherapeutics, Inc. · Sites in Ukraine, Australia, Georgia and 2 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 60 · Phase 3 47 · Phase 4 3
First in 2002; this study’s year is marked. 10 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 260 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 409 across the 115 interventional studies, 809 across the 3 observational. Of the 109 that completed or were terminated, 81 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
118 of 118 have an industry lead sponsor. The 10 most frequent:
This study is registered under Akros Pharma Inc., one of the names counted as Shionogi. Under that name alone:
Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Shionogi has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Rheumatoid with a site in Ukraine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052032Candid TherapeuticsAn Open-label Study of CND261 in Seropositive Rheumatoid Arthritis | 2027-06-01 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 118 studies in Arthritis, Rheumatoid with a site in Ukraine, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: JTE-051
One dose of study drug by mouth daily for 12 weeks
Drug: Placebo
Active drug tablets containing JTE-051
Placebo tablets identical in appearance to the active drug tablets
Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)
Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Time frame: Up to 12 Weeks
Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12
Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Time frame: Week 12
Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12
Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Time frame: Week 12
Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12
Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
Time frame: Week 12
Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12
The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows: 0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity
Time frame: Week 12
Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12
The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows: 0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity
Time frame: Week 12
Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*SGA+0.96. DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
Time frame: Week 12
Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
Time frame: Week 12
Number of Subjects With Treatment-related Adverse Events
Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.
Time frame: Up to 16 Weeks
Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12
Time frame: Week 12
Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.
| Milestone | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Started | 52 | 52 | 52 | 51 | 52 |
| Started dosing | 51 | 52 | 52 | 51 | 52 |
| Completed | 46 | 44 | 47 | 38 | 48 |
| Not completed | 6 | 8 | 5 | 13 | 4 |
| Withdrew: Adverse event | 3 | 3 | 3 | 9 | 2 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 1 | 2 | 2 |
| Withdrew: Inclusion/exclusion criteria not met | 1 | 1 | 1 | 1 | 0 |
Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
| Participants | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT) | 27 | 31 | 27 | 30 | 29 |
Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
| Participants | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12 | 26 | 28 | 25 | 24 | 28 |
Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
| Participants | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12 | 10 | 12 | 8 | 11 | 10 |
Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo. The ACR core set measures are: 1. Tender joint count 2. Swollen joint count 3. Subject Assessment of arthritis pain 4. Subject's Global Assessment of disease activity (SGA) 5. Physician's Global Assessment of disease activity (PGA) 6. Health Assessment Questionnaire Disability Index (HAQ-DI) 7. Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)
| Participants | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12 | 3 | 5 | 4 | 4 | 0 |
The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows: 0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity
| Score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12 | -18.14 ± 15.437 | -21.68 ± 13.275 | -19.41 ± 16.446 | -19.97 ± 14.244 | -17.66 ± 16.816 |
The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows: 0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity
| Score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12 | -18.76 ± 14.768 | -22.40 ± 13.469 | -21.02 ± 16.153 | -21.24 ± 14.208 | -17.19 ± 15.548 |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*SGA+0.96. DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.
| Score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12 | -0.95 ± 1.039 | -1.23 ± 0.979 | -1.03 ± 1.123 | -1.10 ± 0.987 | -0.98 ± 1.123 |
The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.
| Score on a scale | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12 | -0.52 ± 0.600 | -0.71 ± 0.629 | -0.60 ± 0.620 | -0.80 ± 0.727 | -0.47 ± 0.616 |
Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.
| Participants | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| Number of subjects with TEAEs | 26 | 21 | 32 | 34 | 22 |
| Number of subjects with no TEAEs | 25 | 31 | 20 | 17 | 30 |
| ng/mL | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg |
|---|---|---|---|---|
| Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12 | 119 ± 96.9 | 178 ± 156 | 312 ± 252 | 354 ± 281 |
Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JTE-051 50 mg | 0/51 (0%) | 2/51 (3.9%) | 11/51 (21.6%) |
| JTE-051 100 mg | 1/52 (1.9%) | 3/52 (5.8%) | 7/52 (13.5%) |
| JTE-051 150 mg | 0/52 (0%) | 2/52 (3.8%) | 20/52 (38.5%) |
| JTE-051 200 mg | 0/51 (0%) | 1/51 (2%) | 21/51 (41.2%) |
| Placebo | 0/52 (0%) | 0/52 (0%) | 3/52 (5.8%) |
| Event | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 1/51 | 0/52 | 0/52 | 0/51 | 0/52 |
| Cellulitis/Cellulitis in right handInfections and infestations | 1/51 | 0/52 | 0/52 | 0/51 | 0/52 |
| UrticariaSkin and subcutaneous tissue disorders | 0/51 | 0/52 | 0/52 | 1/51 | 0/52 |
| Abdominal pain/Diffused abdominal painGastrointestinal disorders | 0/51 | 1/52 | 0/52 | 0/51 | 0/52 |
| Gastric ulcerGastrointestinal disorders | 0/51 | 0/52 | 1/52 | 0/51 | 0/52 |
| Pneumonia/Bilateral pneumoniaInfections and infestations | 0/51 | 1/52 | 0/52 | 0/51 | 0/52 |
| Rheumatoid arthritis/Exacerbation of rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/51 | 0/52 | 1/52 | 0/51 | 0/52 |
| Insomnia/Sleep Disorders: InsomniaPsychiatric disorders | 0/51 | 1/52 | 0/52 | 0/51 | 0/52 |
| Event | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo |
|---|---|---|---|---|---|
| DysgeusiaNervous system disorders | 2/51 | 1/52 | 2/52 | 9/51 | 0/52 |
| Urinary tract infectionInfections and infestations | 3/51 | 3/52 | 5/52 | 8/51 | 2/52 |
| ConstipationGastrointestinal disorders | 3/51 | 1/52 | 6/52 | 2/51 | 0/52 |
| NasopharyngitisInfections and infestations | 2/51 | 1/52 | 4/52 | 0/51 | 0/52 |
| AnemiaBlood and lymphatic system disorders | 1/51 | 1/52 | 3/52 | 2/51 | 1/52 |
Baseline characteristics results are reported for the Intent-to-Treat (ITT) population: 257 subjects who received at least one dose of JTE-051 or placebo and had at least one post-baseline efficacy assessment during the double-blind treatment period.
| Age, Categorical(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 42 | 48 | 46 | 43 | 44 | 223 |
| >=65 years | 9 | 3 | 6 | 8 | 8 | 34 |
| Sex: Female, Male(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 41 | 40 | 44 | 43 | 43 | 211 |
| Male | 10 | 11 | 8 | 8 | 9 | 46 |
| Ethnicity (NIH/OMB)(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 27 | 27 | 26 | 27 | 26 | 133 |
| Not Hispanic or Latino | 24 | 24 | 26 | 24 | 26 | 124 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | JTE-051 50 mg | JTE-051 100 mg | JTE-051 150 mg | JTE-051 200 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 8 | 8 | 6 | 7 | 3 | 32 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 31 | 34 | 31 | 34 | 33 | 163 |
| More than one race | 12 | 9 | 15 | 10 | 16 | 62 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Jun 2018, 21 months.
Results were first posted in Jun 2021, 2 years 11 months after primary completion. A results delay was requested in Nov 2019.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.